Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Table 3 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort, n (%)

Dependent: Survival (PFS/30, status)		All patients (n = 131)	HR (univariable)	HR (multivariable)
Gender	Male	76 (58.0)	-	-
	Female	55 (42.0)	0.87 (0.60-1.26, P = 0.458)	-
Age	> 60	66 (50.4)	-	-
	≤ 60	65 (49.6)	0.73 (0.50-1.07, P = 0.110)	-
ECOG	0-1	116 (88.5)	-	-
	2	15 (11.5)	1.34 (0.73-2.47, P = 0.340)	-
Number of metastatic organs	1	55 (42.0)	-	-
	≥ 2	76 (58.0)	1.96 (1.32-2.90, P < 0.001)	1.90 (1.27-2.84, P = 0.002)
Primary tumor location	Right colon	32 (24.4)	-	-
	Left colon and rectum	99 (75.6)	0.92 (0.61-1.40, P = 0.697)	-
Liver metastasis	No	46 (35.1)	-	-
	Yes	85 (64.9)	1.57 (1.04-2.36, P = 0.032)	1.28 (0.84-1.96, P = 0.254)
Lung metastasis	No	70 (53.4)	-	-
	Yes	61 (46.6)	1.23 (0.85-1.78, P = 0.274)	-
RAS mutation type	Unknown	25 (19.1)	-	-
	Wild type	20 (15.3)	0.97 (0.51-1.85, P = 0.930)	-
	Mutation	86 (65.6)	1.37 (0.84-2.24, P = 0.202)	-
Group	Control group	105 (80.2)	-	-
	Experimental group	26 (19.8)	0.51 (0.31-0.82, P = 0.006)	0.49 (0.30-0.80, P = 0.004)

n = 131, events = 115, likelihood ratio test = 22.56 on 3 df (P < 0.001). ECOG: Eastern Cooperative Oncology Group; PFS: Progression-free survival; HR: Hazard ratio.